摘要
目的:测定各类型肝炎及失代偿期肝硬化患者血浆中的组织因子途径抑制物(Tissue factor pathway in-hibitor,TFPI),并探索其临床意义。方法:TFPI抗原(TFPI:Ag)测定采用双夹心ELISA抗原测定法,TFPI活性(TFPI:A)测定采用发色底物法。结果:急性中毒性肝炎(n=14)TFPI:Ag为160.3±26.1ng/ml,TFPI:A为515.8±50.2 u/ml;急性病毒性肝炎(n=20)各为197.7±18.6 ng/ml与532.1±98.7 u/ml;慢性乙型肝炎(n=48)各为162.5±28.3ng/ml与636.7±54.8 u/ml;失代偿期肝硬化(n=20)各为81.7±16.7 ng/ml与747.2±81.2u/ml。与对照组相比,TF-PI:Ag(正常值103.2±11.5 ng/ml)除肝硬化组接近正常低值外,其它各组均有增高(P<0.05);TFPI:A(正常值112.5±23.6 u/ml)各组均增高(P<0.01)。结论:炎症时因单核-巨噬细胞活跃及炎症因子刺激血管内皮细胞,故使TFPI过度表达,但在肝硬化时TFPI:Ag已趋向正常低值,可能与门静脉系血栓形成过程中TFPI不断大量消耗有关。
Purpose: The present studies were first to determine the plasma levels of tissue factor path-way inhibitor (TFPI) in several type of hepatitis and decompenstion cirrhosis. Methods: TFPI antigen (TFPI:Ag) was determined with an enzyme linked immunity (ELISA). TFPI: active (TFPI:A) was de-termined with chromogenic peptide substrate method. Results: Acute toxin hepatitis (n=14), acute viral hepatitis (n=20), chronic B type hepatitis (n=48)and decompensation cirrhosis (n=20), TFPI:Ag/ TFPI: A was: 160.3±26.1 ng/ml/515. 8±50.2 u/ml, 197.7±18.6ng/ml/532.1±98.7u/ml, 162.5±28.3 ng/ml/636.7±?54.8u/ml, 81.7±16.7ng/ml/747.2±81.2u/ml respectively. Except for group of cirrhosis, the other groups TFPI: Ag was increased than control(103. 2±?11.5 ng/ml) and TFPI: A were increased than control(112. 5±23.6 u/ml) in all groups. Conclusion: TFPI can over showdown on inflammation due to active of mono-macrophages and endothelial cell of vessel irritated by inflammatory fac-tor. But TFPI: Ag decreased to low levels of normal in group of cirrhosis, be concerned with thrombosis of portal vein system, The TFPI:Ag would decreased in a consumption coagulation.
出处
《临床消化病杂志》
1999年第2期73-74,共2页
Chinese Journal of Clinical Gastroenterology
关键词
肝炎
肝硬化
TFPI
抗凝蛋白
测定
Hepatitis Cirrhosis Tissue factor pathway inhibitor
